UroGen Pharma Ltd.
URGN
$9.66
-$0.01-0.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.51M | -23.67M | -33.40M | -32.29M | -26.02M |
| Total Depreciation and Amortization | 306.00K | 266.00K | 263.00K | 351.00K | 424.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.06M | 5.34M | 6.63M | 3.96M | 5.02M |
| Change in Net Operating Assets | 15.53M | -9.60M | 2.76M | -3.76M | 7.57M |
| Cash from Operations | -13.62M | -27.66M | -23.75M | -31.74M | -13.00M |
| Capital Expenditure | -115.00K | -96.00K | -84.00K | -- | -56.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 60.74M | -106.65M | 12.08M | 13.52M | -11.29M |
| Cash from Investing | 60.62M | -106.75M | 12.00M | 13.52M | -11.34M |
| Total Debt Issued | 0.00 | 24.49M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 71.00K | 15.12M | 81.64M | 54.66M | 40.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 18.64M | -- | 0.00 |
| Cash from Financing | 71.00K | 39.61M | 100.29M | 54.66M | 40.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.07M | -94.81M | 88.54M | 36.44M | -24.30M |